<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01911624</url>
  </required_header>
  <id_info>
    <org_study_id>S54881</org_study_id>
    <nct_id>NCT01911624</nct_id>
  </id_info>
  <brief_title>Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia</brief_title>
  <official_title>Direct Thrombin Inhibitors Versus LMWH in Staphylococcus Aureus Bacteraemia. A Prospective Randomized Controlled Academic Single-centre Feasibility Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and efficacy of direct thrombin inhibitors versus enoxaparin in patients with
      staphylococcus aureus bacteraemia.

      The study hypothesizes that inhibition of the coagulase-activity of S. aureus by direct
      thrombin inhibitors is safe and translates into a better outcome of patients with S. aureus
      bacteremia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single center randomized controlled trial of direct thrombin inhibitors versus standard
      enoxaparin.

        -  Feasibility: proportion of patients eligible for randomization; clinically attained
           concentration of DTI and resulting staphylothrombin inhibition

        -  Safety: bleeding events (major/ clinically relevant non-major)

        -  Efficacy: thrombotic events during the thromboprophylactic treatment + 3 days

        -  Secondary outcome measures

             -  Coagulation parameters: evolution of D-dimers from day 0-4; other lab parameters of
                coagulation (PT/APTT/fibrinogen/platelet count)

             -  Inflammatory parameters: CRP, white blood cell count, neutrophilia

             -  Clinical outcomes: metastatic infections, assessed clinically or by PET/CT; relapse
                of S. aureus bacteremia; defervescence; persistent positive blood cultures;
                hospital stay, mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Outcome is the occurence of clinically-relevant bleeding events</measure>
    <time_frame>From date of randomization up to end of study drug + 3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The primary efficacy outcome is the occurence of metastatic infection</measure>
    <time_frame>From randomization until month 3</time_frame>
    <description>as documented with a PET-CTscan in eligible patients on D7-10 or clinically-overt metastatic infectious foci</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Laboratory markers of coagulation</measure>
    <time_frame>From randomization until D7-10</time_frame>
    <description>D-dimeren, fibrinogen, APTT, PT dabigatran level or antiXa</description>
  </other_outcome>
  <other_outcome>
    <measure>Laboratory markers of inflammation</measure>
    <time_frame>From randomization until D7-10</time_frame>
    <description>CRP</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinical outcomes after S. aureus bacteremia</measure>
    <time_frame>From randomization until M3</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Staphylococcus Aureus Bacteraemia</condition>
  <arm_group>
    <arm_group_label>direct thrombin inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dabigatran 110 mg BID, po argatroban (0.5 - 1 Âµg/kg/min) if peroral therapy is not possible</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>enoxaparin 40 mg od, sc</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>direct thrombin inhibition</intervention_name>
    <arm_group_label>direct thrombin inhibition</arm_group_label>
    <other_name>dabigatran</other_name>
    <other_name>argatroban</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin</intervention_name>
    <arm_group_label>enoxaparin</arm_group_label>
    <other_name>clexane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive blood culture for staphylococcus aureus

          -  Symptoms or signs of infection

          -  Indication for thromboprophylaxis

        Exclusion Criteria:

          -  Contraindication for thromboprophylaxis

          -  Significant active bleeding or risk of excessive bleeding

          -  Heparin-induced thrombocytopenia

          -  Severe liver and kidney disease

          -  Pregnancy and lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Verhamme, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bloedings-en vaatziekten, UZ Gasthuisberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KUleuven/UZ Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2013</study_first_submitted>
  <study_first_submitted_qc>July 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2013</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Peter Verhamme</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Argatroban</mesh_term>
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

